Cross-Sector entity
Of the tracked stories, 3 of 6 also mention Arcturus Therapeutics, the most common co-covered peer. Coverage clusters in earnings, which accounts for 2 of those 6, with the remainder spread across 2 other categories. 0% of these stories carry negative sentiment.
6 verified stories tracked
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 6 also mention Arcturus Therapeutics, the most common co-covered peer. Coverage clusters in earnings, which accounts for 2 of those 6, with the remainder spread across 2 other categories. 0% of these stories carry negative sentiment. We currently track 6 Cross-Sector stories that mention Rigel Pharmaceuticals, published between March 2, 2026 and March 5, 2026. The tracked stories average 2 original sources each.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rigel Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Release
Both companies scheduled to report full-year 2025 financial results.
ARCT-032 Phase 1b
Arcturus releases positive interim data for Cystic Fibrosis candidate.
Kostaive Approval
Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.
Cumberland and Rigel Pharmaceuticals reported Q4 2025 results, highlighting strategic shifts toward high-margin specialty products and oncology expansions. While Cumberland focuses on hospital-channel optimization, Rigel is doubling down on its hematology-oncology portfolio to drive long-term growth.
Rigel Pharmaceuticals and Cumberland Pharmaceuticals reported Q4 results that emphasize commercial execution and a shift toward sustainable profitability. Both companies are leveraging core hospital and oncology assets to navigate a market that increasingly rewards revenue-generating biotechs over speculative R&D.
Rigel and Cumberland Pharmaceuticals reported Q4 results highlighting steady commercial growth in specialty oncology and hospital-based therapies. Both companies are prioritizing portfolio optimization and pipeline advancement to navigate a competitive biotech landscape.
Source: finance.yahoo.com · finance.yahoo.com
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.
Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Source: Seeking Alpha · Seeking Alpha
